A mGlu2/3 Agonist in the Treatment of PTSD

Based on the public registry summary, this study is trying to understand: In this study, we propose to employ a randomized, double-blind, placebo-controlled, outpatient clinical trial to test the efficacy, safety, and tolerability of a 160 mg and 40 mg challenge of the mGlu2/3 agonist pomaglumetad methionil relative to placebo in modulating. The study team can confirm the exact objective and what it means for you.

This appears to be a medication / drug study involving Pomaglumetad Methionil 160mg, Pomaglumetad Methionil 40mg, Placebo. The listed phase is PHASE1. Ask the study team what that means in practice for safety, monitoring, and criteria.

This study may concern people with ptsd; age range: From 18 Years to 60 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

This study is sponsored by NYU Langone Health, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status. The registry lists an estimated enrollment of 10 participants.